NASDAQ:MGNX MacroGenics (MGNX) Stock Forecast, Price & News $5.10 -0.05 (-0.97%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$5.00▼$5.2350-Day Range$5.10▼$7.5452-Week Range$2.13▼$7.90Volume601,400 shsAverage Volume578,651 shsMarket Capitalization$315.38 millionP/E RatioN/ADividend YieldN/APrice Target$11.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability MacroGenics MarketRank™ ForecastAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside123.5% Upside$11.40 Price TargetShort InterestBearish8.15% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.63Based on 2 Articles This WeekInsider TradingSelling Shares$32,393 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.62) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector663rd out of 1,010 stocksPharmaceutical Preparations Industry337th out of 494 stocks 3.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Buy. The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.40, MacroGenics has a forecasted upside of 123.5% from its current price of $5.10.Amount of Analyst CoverageMacroGenics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.15% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in MacroGenics has recently increased by 1.06%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 2.0 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MacroGenics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,393.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions93.63% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.62) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MacroGenics (NASDAQ:MGNX) StockMacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.Read More Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Stock News HeadlinesMay 23, 2023 | americanbankingnews.comBrokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Price Target at $11.33May 22, 2023 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Upgraded at StockNews.comMay 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 14, 2023 | finance.yahoo.comThese Analysts Just Made An Incredible Downgrade To Their MacroGenics, Inc. (NASDAQ:MGNX) EPS ForecastsMay 14, 2023 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Downgraded by StockNews.comMay 14, 2023 | americanbankingnews.comBrokers Set Expectations for MacroGenics, Inc.'s Q2 2023 Earnings (NASDAQ:MGNX)May 12, 2023 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Given New $10.00 Price Target at JMP SecuritiesMay 11, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for MacroGenics (MGNX)May 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 10, 2023 | finanznachrichten.deMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comEarnings Outlook For MacrogenicsMay 10, 2023 | apnews.comMacroGenics: Q1 Earnings SnapshotMay 10, 2023 | markets.businessinsider.comMacroGenics (MGNX) Gets a Buy from BTIGMay 10, 2023 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Earnings Call TranscriptMay 10, 2023 | finance.yahoo.comMacroGenics (MGNX) Q1 2023 Earnings Call TranscriptMay 9, 2023 | finance.yahoo.comMacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial ResultsMay 8, 2023 | americanbankingnews.comMacroGenics (MGNX) Set to Announce Earnings on TuesdayMay 5, 2023 | finance.yahoo.comMacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Is Matching Sentiment Around Its RevenuesMay 4, 2023 | finance.yahoo.comMacroGenics Announces Date of First Quarter 2023 Financial Results Conference CallApril 28, 2023 | americanbankingnews.comBrokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Price Target at $11.11April 25, 2023 | finance.yahoo.comMacroGenics (MGNX) to Report Q1 Results: Wall Street Expects Earnings GrowthApril 7, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn SituationApril 5, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for MacroGenics, Inc. (NASDAQ:MGNX) Increased by AnalystApril 5, 2023 | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Receives $11.11 Consensus PT from AnalystsApril 3, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on MacroGenics (MGNX)April 3, 2023 | americanbankingnews.comMacroGenics' (MGNX) "Buy" Rating Reaffirmed at HC WainwrightMarch 24, 2023 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Price Target Increased to $12.00 by Analysts at BTIG ResearchSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Company Calendar Last Earnings3/15/2023Today5/29/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees427Year Founded2000Price Target and Rating Average Stock Price Forecast$11.40 High Stock Price Forecast$17.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+123.5%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net Margins-55.24% Pretax Margin-55.24% Return on Equity-70.69% Return on Assets-35.21% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio6.30 Sales & Book Value Annual Sales$151.94 million Price / Sales2.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.77 per share Price / Book2.88Miscellaneous Outstanding Shares61,840,000Free Float55,655,000Market Cap$315.38 million OptionableOptionable Beta2.00 Social Links Key ExecutivesScott E. KoenigPresident, Chief Executive Officer & DirectorEric RisserChief Operating OfficerJames KarrelsChief Financial Officer, Secretary & Senior VPEzio BonviniChief Scientific Officer & Senior VP-ResearchThomas M. SpitznagelSenior Vice President-Technical OperationsKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSTango TherapeuticsNASDAQ:TNGXVera TherapeuticsNASDAQ:VERAPepGenNASDAQ:PEPGPrecigenNASDAQ:PGENView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 17,530 shares on 5/22/2023Ownership: 0.050%JPMorgan Chase & Co.Sold 33,755 shares on 5/18/2023Ownership: 0.327%New York State Common Retirement FundSold 17,128 shares on 5/18/2023Ownership: 0.030%Susquehanna Fundamental Investments LLCSold 5,002 shares on 5/16/2023Ownership: 0.085%Jane Street Group LLCBought 11,211 shares on 5/16/2023Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions MGNX Stock - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price forecast for 2023? 11 equities research analysts have issued 12 month target prices for MacroGenics' stock. Their MGNX share price forecasts range from $5.00 to $17.00. On average, they predict the company's share price to reach $11.40 in the next year. This suggests a possible upside of 123.5% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2023? MacroGenics' stock was trading at $6.71 on January 1st, 2023. Since then, MGNX stock has decreased by 24.0% and is now trading at $5.10. View the best growth stocks for 2023 here. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) issued its quarterly earnings results on Wednesday, March, 15th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.51. The biopharmaceutical company earned $73.10 million during the quarter, compared to analysts' expectations of $75.40 million. MacroGenics had a negative trailing twelve-month return on equity of 70.69% and a negative net margin of 55.24%. What ETFs hold MacroGenics' stock? ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." Who are MacroGenics' major shareholders? MacroGenics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.70%), Armistice Capital LLC (9.64%), Wasatch Advisors LP (2.14%), State Street Corp (2.11%), Acadian Asset Management LLC (1.99%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $5.10. How much money does MacroGenics make? MacroGenics (NASDAQ:MGNX) has a market capitalization of $315.38 million and generates $151.94 million in revenue each year. The biopharmaceutical company earns $-119,760,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. How many employees does MacroGenics have? The company employs 427 workers across the globe. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321. This page (NASDAQ:MGNX) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.